$2.53
7.20% day before yesterday
Nasdaq, Jul 03, 10:53 pm CET
ISIN
US45782T1051
Symbol
INMB
Sector
Industry

Inmune Bio, Inc. Stock price

$2.53
-4.74 65.20% 1M
-2.77 52.22% 6M
-2.14 45.82% YTD
-5.46 68.34% 1Y
-6.24 71.15% 3Y
-2.47 49.40% 5Y
-5.46 68.34% 10Y
-5.46 68.34% 20Y
Nasdaq, Closing price Thu, Jul 03 2025
+0.17 7.20%
ISIN
US45782T1051
Symbol
INMB
Sector
Industry

Key metrics

Basic
Market capitalization
$67.3m
Enterprise Value
$47.9m
Net debt
positive
Cash
$19.3m
Shares outstanding
22.9m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
1,345.2 | 2,637.6
EV/Sales
958.4 | 1,879.2
EV/FCF
negative
P/B
2.0
Financial Health
Equity Ratio
81.1%
Return on Equity
-131.1%
ROCE
-139.0%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$50.0k | $25.5k
EBITDA
- | -
EBIT
$-41.5m | -
Net Income
$-40.8m | $-40.2m
Free Cash Flow
$-32.7m
Growth (TTM | estimate)
Revenue
-61.5% | 155.0%
EBITDA
- | -
EBIT
-20.9%
Net Income
-18.3% | 4.4%
Free Cash Flow
-78.6%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-83,046.0%
Net
-81,592.0% | -157,758.4%
Free Cash Flow
-65,418.0%
More
EPS
$-1.8
FCF per Share
$-1.4
Short interest
38.5%
Employees
18
Rev per Employee
$0.0
Show more

Is Inmune Bio, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,966 stocks worldwide.

Inmune Bio, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Inmune Bio, Inc. forecast:

8x Buy
73%
2x Hold
18%
1x Sell
9%

Analyst Opinions

11 Analysts have issued a Inmune Bio, Inc. forecast:

Buy
73%
Hold
18%
Sell
9%

Financial data from Inmune Bio, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
0.05 0.05
62% 62%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 9.46 9.46
2% 2%
18,920%
- Research and Development Expense 32 32
29% 29%
64,220%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -42 -42
21% 21%
-83,046%
Net Profit -41 -41
18% 18%
-81,600%

In millions USD.

Don't miss a Thing! We will send you all news about Inmune Bio, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Inmune Bio, Inc. Stock News

Neutral
Seeking Alpha
about one hour ago
INmune Bio's XPro missed its Phase II primary endpoint, but subgroup data and safety profile suggest potential for targeted Alzheimer's patients with neuroinflammation. Despite the setback, I see significant upside from XPro and CORDStrom, with blockbuster potential if approved, given INMB's tiny current market cap. Risks include uncertain XPro efficacy, need for more capital, and dilution; I m...
Neutral
GlobeNewsWire
4 days ago
Boca Raton, Florida, June 30, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company, today announced that it has closed its registered direct offering, announced on June 27, 2025, (the "Offering") for the purchase and sale of 3,000,000 shares of its common stock at a purchase price of $6.30 per share, priced at-the-market u...
Negative
Proactive Investors
4 days ago
INmune Bio Inc (NASDAQ:INMB) shares plummeted almost 60% following disappointing results from a Phase 2 clinical trial of its experimental Alzheimer's drug, XPro. The drug failed to meet the primary cognitive endpoint in the overall intent-to-treat population, meaning it did not significantly improve cognitive function over six months compared to placebo in early Alzheimer's patients.
More Inmune Bio, Inc. News

Company Profile

INmune Bio, Inc. focuses on controlling components of the immune system to activate an immune response against cancer and Alzheimer's disease. Its product pipeline INKMUNE-Cancer, INB03-Cancer, XPRO1595-Alzheimer, and LIVNATE. The company was founded by Mark Lowdell in September 2015 and is headquartered in La Jolla, CA.

Head office United States
CEO Raymond Tesi
Employees 18
Founded 2015
Website www.inmunebio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today